Esophageal Squamous Cell Carcinoma Clinical Trials in Zhengzhou, Henan
5 recruitingZhengzhou, Henan, China
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC230 enrolled59 locationsNCT05319730
Recruiting
Phase 1Phase 2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC298 enrolled43 locationsNCT06780111
Recruiting
Phase 2
Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer
Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University208 enrolled1 locationNCT07016724
Recruiting
Phase 3
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital219 enrolled2 locationsNCT05495152
Recruiting
Phase 3
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital456 enrolled1 locationNCT04138212